SALT
LAKE CITY, Oct. 2, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that Co-Diagnostics will be hosting a booth at the
Utah Health Care Association/Utah Center for Assisted Living
(UHCA/UCAL) Convention & Expo at the Mountain America Expo
Center in Sandy, Utah on
October 2-3, 2024.
The UHCA/UCAL Convention includes sessions and events for
executive leadership, administrators, corporate personnel, owners,
and Directors of Nursing for skilled nursing, assisted living and
intermediate care facilities, and will include an expo for
companies to exhibit their products and services relevant to these
industries. The Co-Dx™ booth will showcase the Company's upcoming
Co-Dx PCR platform*, including the menu of at-home and
point-of-care tests in development.
More information about the convention, including registration
details and exhibition times, can be found here. Parties interested
in learning more about the Company's diagnostic products and how
they can be utilized in this sector are invited to visit Booth
300.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx
PCR Pro™, mobile app, and all associated tests and software) is
subject to review by the FDA and/or other regulatory bodies and is
not available for sale. The Co-Dx PCR Pro instrument and Co-Dx
COVID-19 Test are currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding our preparation for
introducing a new PCR diagnostic platform designed for at-home and
point-of-care use that would be relevant to skilled nursing,
assisted living, and intermediate care facilities. Actual
results may differ materially from those contemplated or
anticipated by such forward-looking statements. Readers of this
press release are cautioned not to place undue reliance on any
forward-looking statements. There can be no assurance that any of
the anticipated results will occur on a timely basis or at all due
to certain risks and uncertainties, a discussion of which can be
found in our Risk Factors disclosure in our Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC)
on March 14, 2024, and in our other filings with the SEC. The
Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-the-2024-uhcaucal-fall-convention--expo-on-oct-2-3-302265287.html
SOURCE Co-Diagnostics